Connect with us

Hi, what are you looking for?

Business

Amgen Declares Third Quarter Dividend of $2.38 Per Share

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

Amgen has announced a dividend of $2.38 per share for the third quarter of 2025. This decision was made by the company’s Board of Directors and marks a significant return for investors. The dividend is scheduled for payment on September 12, 2025, to shareholders who are on record as of the close of business on August 22, 2025.

Based in Thousand Oaks, California, Amgen has been a pioneer in the biotechnology sector for over 40 years. The company has developed a robust portfolio of innovative medicines aimed at treating a variety of serious illnesses, including cancer, heart disease, and rare diseases.

In its continuing effort to advance medical science, Amgen utilizes cutting-edge technology and human genetic data to develop treatments. In 2024, the company was recognized by Fast Company as one of the “World’s Most Innovative Companies.” Additionally, it earned accolades from Forbes, which named it one of “America’s Best Large Employers.” These recognitions highlight Amgen’s commitment to both employee satisfaction and innovation.

Amgen is also a prominent member of major stock indices, including the Dow Jones Industrial Average and the Nasdaq-100 Index. These listings reflect the company’s stature and market capitalization as one of the largest non-financial companies traded on the Nasdaq Stock Market.

The announcement of the dividend comes amidst a backdrop of ongoing strategic collaborations and acquisitions aimed at enhancing Amgen’s product pipeline. The company has entered into collaborations with firms such as BeOne Medicines Ltd. and Kyowa Kirin Co., Ltd., and has also acquired ChemoCentryx, Inc. and Horizon Therapeutics plc. These efforts are intended to bolster Amgen’s ability to deliver innovative therapies and expand its market reach.

As with any forward-looking statements, there are inherent risks and uncertainties associated with Amgen’s operations. The company acknowledges challenges such as competition from other pharmaceutical products, regulatory hurdles, and potential supply chain disruptions. Amgen’s ability to maintain its dividend and continue fulfilling its financial commitments may be influenced by these factors.

For more detailed information about Amgen’s operations, products, and financial performance, visit the company’s official website at Amgen.com or follow them on social media platforms including X, LinkedIn, Instagram, YouTube, and Threads.

In conclusion, Amgen’s declaration of a $2.38 dividend signals its ongoing commitment to reward shareholders while pursuing its mission to improve patient outcomes through innovative medical solutions.

You May Also Like

Top Stories

California has taken a stand against a federal directive from the Trump administration demanding the exclusion of transgender athletes from girls’ and women’s sports....

Entertainment

Olivia Munn, the acclaimed actress, recently shared an intimate revelation about her personal struggles with trichotillomania, a disorder that compels individuals to pull out...

Top Stories

URGENT UPDATE: Affordable motorcycle helmets under ₹1000 are now available for safety-conscious riders across India. With road safety becoming a pressing issue, these helmets...

Top Stories

Frontier, a coalition of technology leaders including Google and Meta, has announced a landmark investment in Arbor, a cutting-edge startup specializing in bioenergy with...

Sports

HBO Max has released the official trailer for the highly anticipated second season of Peacemaker, featuring John Cena in the lead role. The unveiling...

Entertainment

Fans of My Chemical Romance were taken aback after revelations emerged about guitarist Frank Iero‘s past encounter with the FBI. The incident traces back...

Science

New observations from the James Webb Space Telescope (JWST) are transforming our understanding of Europa, one of Jupiter’s moons. These findings reveal that the...

Health

Ng Kuo Pin, CEO of NCS, announced a significant investment of S$130 million in artificial intelligence (AI) over the next three years. This initiative...

Politics

Lawmakers in Pennsylvania are exploring potential changes to the state’s sales tax exemptions as the General Assembly grapples with a significant budget deficit. This...

Business

Political commentator Brilyn Hollyhand has voiced strong opposition to the prospect of Elon Musk launching a third political party in 2025. In his commentary,...

Top Stories

UPDATE: Meta Platforms just announced a staggering $14.8 billion investment in AI, ramping up its efforts to dominate the tech landscape. This move comes...

Top Stories

The Trump Justice Department has not released a client list related to the late financier Jeffrey Epstein, despite widespread speculation and anticipation. This decision...

Copyright © All rights reserved. This website provides general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information presented. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult appropriate experts when needed. We are not responsible for any loss or inconvenience resulting from the use of information on this site.